Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Could we personalise 1

line treatment?

N=35 (crizotinib 1

TKI)

N=51 (crizotinib, certinib, alectinib)

Yoshida – JCO 2016 * Woo – Ann Oncol 2017 * Dziadziuszko– ESMO 2018

EML4-ALK

variant V3, shorter PFS with ALK TKI

V3a- cells resistance to all ALK TKI, with IC

>500 nM

Brigatinib?

Lorlatinib?

ALEX